Concord Biotech Limited (NSE:CONCORDBIO)

India flag India · Delayed Price · Currency is INR
1,209.50
+5.80 (0.48%)
Mar 6, 2026, 1:40 PM IST
-30.78%
Market Cap 125.93B
Revenue (ttm) 11.59B
Net Income (ttm) 3.13B
Shares Out 104.62M
EPS (ttm) 29.69
PE Ratio 40.55
Forward PE 31.03
Dividend 10.70 (0.89%)
Ex-Dividend Date n/a
Volume 32,077
Average Volume 1,147,222
Open 1,203.70
Previous Close 1,203.70
Day's Range 1,188.60 - 1,214.00
52-Week Range 1,068.60 - 2,150.40
Beta 0.24
RSI 50.45
Earnings Date Feb 11, 2026

About Concord Biotech

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin,... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1984
Employees 1,571
Stock Exchange National Stock Exchange of India
Ticker Symbol CONCORDBIO
Full Company Profile

Financial Performance

In fiscal year 2025, Concord Biotech's revenue was 12.00 billion, an increase of 18.01% compared to the previous year's 10.17 billion. Earnings were 3.72 billion, an increase of 20.62%.

Financial Statements

News

There is no news available yet.